Letters to the Editor
Volume 2 / Year 2013 / Issue 4
Biosimilars naming and prescribing policy in Australia
Page: 168-9
Submitted: 31 October 2013; Revised: 6 November 2013; Accepted: 11 November 2013; Published online first: 25 November 2013 To the Editor: I wanted to bring to your attention the following… Read More »
WHO leadership in public safety on biosimilars to be commended
Page: 167
Abstract: As a practicing endocrinologist and Chairman of the Alliance for Safe Biologic Medicines, I am writing to commend the World Health Organization for its attention to and upcoming action… Read More »
Critical immunogenicity differences will be obscured by a common INN for biosimilars
Page: 166
Abstract: Information about variable immunogenicity arising from formulation differences between competing biosimilars is critical for informed judgments by prescribing physicians. Use of a common INN for biosimilars will obfuscate such… Read More »
Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation
Page: 165
Abstract: Legislation in support of pharmacist notification to patients and providers of substitution of an interchangeable biologic for the originator biologic was recently vetoed in California. Automatic substitution of approved… Read More »